Investigational drug · Phase 3
BGB-43395
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HR+/HER2- Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "BGB-43395"
First trial start
2026
May 22, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGB-43395", any sponsor or status.
Conditions studied
As listed on its trial records.
- HR+/HER2- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BGB-43395" as an intervention, largest first.
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07492641 · 1,056 participants (planned) · Start May 22, 2026 · Primary completion Apr 2029
Drug: BGB-43395; Letrozole and 3 more · For: HR+/HER2- Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 241 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06120283 · 433 participants (planned) · Start Dec 1, 2023 · Primary completion Dec 2029
Drug: BGB-43395; Fulvestrant and 3 more · For: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer and 5 more
Sites: Denver, Colorado; Lake Mary, Florida; Detroit, Michigan · 61 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06756932 · 120 participants (planned) · Start Feb 4, 2025 · Primary completion Jul 30, 2027
Drug: BGB-21447; Fulvestrant and 1 more · For: Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer
Sites: Iowa City, Iowa; Houston, Texas; Seattle, Washington · 14 sites in all
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07226349 · 105 participants (planned) · Start Dec 11, 2025 · Primary completion Nov 1, 2028
Drug: BG-75098; BGB-43395 and 1 more · For: Advanced Solid Tumor
Sites: Birmingham, Alabama; Duarte, California; New Haven, Connecticut · 23 sites in all
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruiting
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT06257264 · 103 participants · Start Mar 11, 2024 · Primary completion Aug 27, 2026
Drug: BG-68501; Fulvestrant and 1 more · For: Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer and 9 more
Sites: Newport Beach, California; Lake Mary, Florida; St Louis, Missouri · 24 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT06761898 · 51 participants · Start Jan 14, 2025 · Primary completion May 20, 2025
Drug: BGB-43395; BGB-43395 · For: Healthy Volunteers
Sites: Daytona Beach, Florida
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06253195 · 33 participants · Start Apr 1, 2024 · Primary completion Apr 23, 2026
Drug: BGB-43395; Fulvestrant and 1 more · For: Advanced Solid Tumor; Metastatic Solid Tumor; Hormone-receptor-positive Breast Cancer and 4 more
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 7 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07820891 · 24 participants (planned) · Start Sep 25, 2026 · Primary completion Nov 22, 2026
Drug: BGB-43395; Midazolam and 3 more · For: Healthy Adult Participants
Sites: Dallas, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HR+/HER2- Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.